FindTrial
Sign In

To study the usefulness of enzyme i.e cyclooxygenase II in prediction of outcome of breast cancer in comparison to other predictive factors

TO STUDY THE UTILITY OF COX-2 AS IMMUNOHISTOCHEMICAL PROGNOSTIC MARKER IN COMPARISON TO VARIOUS HISTOPATHOLOGICAL PARAMETERS AND TNM STAGING IN BREAST CARCINOMA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/05/053161
Enrollment
65
Registered
2023-05-26
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

None listed

Sponsors

Indian Council of medical research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All female patient diagnosed with breast cancer and have not received an neo adjuvant chemotherapy

Exclusion criteria

Exclusion criteria: All male patients with breast cancer

Design outcomes

Primary

MeasureTime frame
increased expression of COX-2 suggests poor prognosis in breast cancerTimepoint: within 2 years—

Secondary

MeasureTime frame
To establish pathological TNM staging of carcinoma breastTimepoint: within 2 years—

Countries

India

Contacts

Public ContactDr JAYASHREE BHAWANI

Jawahar lal nehru medical college

Samarth21174@gmail.com8830267710

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026